Literature DB >> 12445958

Overtreatment in children with epilepsy.

Gregory L Holmes1.   

Abstract

Children with epilepsy are at risk for overtreatment, defined as the use of an excessive number or amount of antiepiletic drugs (AEDs). While the extent of overtreatment of epilepsy in children is not known, there is increasing awareness that overtreatment with AEDs contributes to the morbidity associated with childhood epilepsy. Reasons for overtreatment include using AEDs in a child with seizures who does not require therapy, choosing an inappropriate AED for the seizure type or syndrome; treating non-epileptic behaviors as seizures, use of polytherapy when monotherapy would suffice, and inadequate therapeutic options. Despite the introduction of eight new AEDs in the United States during the last decade, many children continue to be treated with the older generation sedative AEDs. Numerous investigators have now demonstrated that sedative AEDs can be safely removed from the drug regimen of children with epilepsy with resultant improvement in behavior, alertness, and improved seizure control. However, the biggest obstacle to overtreatment is the lack of effective therapies for many of the childhood epileptic syndromes. Until there are more effective therapies developed it is highly likely that children will continue to be over-medicated on ineffective and detrimental AEDs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445958     DOI: 10.1016/s0920-1211(02)00183-3

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

1.  Impaired cognition in rats with cortical dysplasia: additional impact of early-life seizures.

Authors:  Marcella M Lucas; Pierre-Pascal Lenck-Santini; Gregory L Holmes; Rod C Scott
Journal:  Brain       Date:  2011-05-20       Impact factor: 13.501

Review 2.  Overtreatment in epilepsy: how it occurs and how it can be avoided.

Authors:  Emilio Perucca; Patrick Kwan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

4.  Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects.

Authors:  Erik K St Louis
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.